Blood Testing Market to Surpass USD 249.7 Billion by 2035, Fueled by POC, AI, and Rising Chronic Disease Burden - TMR

The global Blood Testing Market is projected to grow from US$ 104.4 billion in 2024 to over US$ 249.7 billion by 2035, registering a strong CAGR of 8.2% during 2025-2035, according to the latest industry report. Growth is being driven by the escalating prevalence of chronic diseases, technological advances in point-of-care (POC) testing and lab automation, and expanding adoption of blood-based diagnostics in preventive and personalized medicine.

Gain an understanding of key findings from our Report in this sample -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2517

Analysts' Viewpoint: Diagnostics at the Center of Preventive and Precision Care
Analysts observe that blood testing is transitioning from episodic lab services to continuous, integrated diagnostic ecosystems that support early detection, disease monitoring, and therapeutic decision-making. Innovations-such as lab-on-a-chip, AI-enabled analyzers, and minimally invasive sampling-are democratizing access to high-quality diagnostics and enabling remote care models.

"Blood tests are increasingly embedded into clinical pathways and consumer health journeys," said the report's lead analyst. "As validated blood-based biomarkers and next-gen testing platforms proliferate, diagnostics will play a larger role in lowering disease burden and guiding targeted therapies."

Key Market Drivers
1. Rising Prevalence of Chronic and Infectious Diseases
Growing incidence of diabetes, cardiovascular disease, cancer, and infectious diseases increases demand for routine and specialized blood tests (e.g., glucose, lipid panels, A1C, tumor markers, infectious disease panels) for early detection, monitoring, and therapeutic management.

2. Rapid Technological Advancements
Automated high-throughput analyzers, multiplex assays, lab-on-a-chip platforms, and AI-powered interpretation tools are improving turnaround time, accuracy, and scalability-enabling point-of-care and decentralized testing in clinics, pharmacies, and homes.

3. Expansion of Home-Based and Remote Testing
Home collection kits, fingertip micro-sampling, and telehealth integration are driving consumer adoption of convenient, reliable blood tests for chronic-disease management and preventive screening-creating new revenue streams and care models.

Product & Test Insights
Glucose Testing Remains a Cornerstone
Glucose testing-spanning self-monitoring strips, continuous glucose monitoring, and lab assays-continues to dominate volumes due to the global diabetes burden and routine self-management needs. Emerging digital health integrations (CGM-cloud platforms) are further cementing its leadership.

High-Growth Areas

Liquid biopsy and oncology markers (e.g., circulating tumor DNA, Guardant-style assays) are expanding screening and monitoring use cases.

Neurodegenerative and cognitive biomarkers (recent FDA-cleared plasma pTau/Aβ assays) are enabling less-invasive pathways for Alzheimer's disease evaluation.

Point-of-care infectious disease and cardiac markers are shortening time-to-treatment in acute settings.

Review our comprehensive report to access critical insights -

https://www.transparencymarketresearch.com/blood-testing-market.html

Regional Outlook
North America Leads
North America accounts for the largest market share, supported by advanced healthcare infrastructure, favorable reimbursement frameworks, robust R&D, and rapid adoption of novel diagnostics.

Asia-Pacific: Rapid Expansion
Asia-Pacific is the fastest-growing regional market due to rising healthcare access, expanding diagnostic labs, growing chronic-disease prevalence, and investments in healthcare infrastructure across China, India, Japan, and ASEAN countries.

Competitive Landscape & Key Players
The market is driven by a mix of global diagnostics majors, specialized molecular and companion-diagnostics companies, and digital-health startups. Notable players include: Abbott, F. Hoffmann-La Roche, Thermo Fisher Scientific, Bio-Rad, bioMérieux, Quest Diagnostics, Grifols, Sysmex Corporation, Guardant Health, GRAIL, Everlywell, Freenome, Hologic, and Trinity Biotech. Companies are focusing on partnerships, acquisitions, and regulatory clearances to expand test menus, scale manufacturing, and enter new care settings.

Recent Notable Developments
May 2025: Fujirebio received FDA 510(k) clearance for its LumipulseG pTau 217/β-Amyloid 1-42 Plasma Ratio IVD, the first FDA-cleared plasma-based test to aid evaluation of amyloid pathology in cognitive decline.

July 2024: Guardant Health's Shield blood test was approved for colorectal cancer screening in adults aged 45+-the first FDA-cleared blood test for CRC screening meeting Medicare coverage requirements.

Dec 2024: BD and Babson Diagnostics expanded fingertip blood collection/testing solutions for ambulatory settings, boosting decentralized testing capacity across U.S. health systems.

Challenges & Opportunities
Challenges include regulatory complexity, high cost of advanced molecular tests, workforce shortages in laboratory medicine, and infrastructure gaps in low-resource regions. Key opportunities lie in expanding home testing, integrating diagnostics with digital therapeutics, developing companion diagnostics for targeted therapies, and scaling affordable POC solutions for emerging markets.

Buy this Premium Research Report to access critical market intelligence -

https://www.transparencymarketresearch.com/checkout.php?rep_id=2517<ype=S

Outlook
With diagnostics increasingly central to modern healthcare, the blood testing market is poised for sustained growth driven by technological innovation, increasing screening programs, and the move towards decentralized and preventive care. Successful players will couple validated assays with seamless digital workflows, scalable manufacturing, and strong regulatory strategies to capture the expanding market.

Explore More Reports:

Specimen Collection Cards Market - https://www.transparencymarketresearch.com/specimen-collection-cards-market.html

Lateral Flow Assay Market - https://www.transparencymarketresearch.com/lateral-flow-assay-market.html

Infectious Disease Rapid Diagnostics Devices Market - https://www.transparencymarketresearch.com/infectious-disease-rapid-diagnostics-devices-market.html

In vitro Diagnostics Market - https://www.transparencymarketresearch.com/in-vitro-diagnostics-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

This release was published on openPR.